Physician
Oncology
Dr. Yazan Alsayed, MD
|
|
Give Review
Yazan Alsayed works in the field of Oncology. Yazan Alsayed, MD is a published doctor. He has 27 papers published. The most current publication "The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein." He is registered with Medicare.
Publications
- Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total T...
- International staging System and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and ...
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide...
- High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
- Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
- Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
- Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic dis...
- Proteomics Analysis in post-transplant lymphoproliferative disorders.
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
- Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
- Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
- Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
- Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas...
- Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
- Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
- Proteomic Analysis of waldenstrom macroglobulinemia.
- High serum-free light chain levels and their rapid reDuction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
- Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
- Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
- Engagement of the CrkL adapter in interleukin-5 signaling in eosinophils.
- The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein.
Schools
Aleppo University
University Of Aleppo School Of Medicine
Brookdale University Hospital amp Medical Center
University Of Pittsburgh Medical Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Pittsburgh Medical Center -
Brookdale University Hospital and Medical Center -
University of Aleppo Faculty of Medicine
Drug Facts
| NPI NUMBER | 1558460626 | |
| NPPES Provider LastName | ALSAYED | |
| NPPES Provider FirstName | YAZAN | |
| NPPES Provider ZIPCode | 325048615 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 409.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 28.0 | |
| Percent Opioid Claims | 6.85 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558460626 |
| Last Name Of The Provider | ALSAYED |
| First Name Of The Provider | YAZAN |
| View All |
Similar Doctors
|
Dr. Harish K. Malhotra, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Rasha N. Beg, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David E. Mann Jr., MD |
|
Dr. Harvey Y. Hsiang, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Harish K. Malhotra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David F. Andrews III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sherif Ibrahim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter L. Kennedy, MD
This Doctor is OpenDoctor Recommended.
|